A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function
Open Access
- 21 April 2006
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 62 (3) , 297-303
- https://doi.org/10.1111/j.1365-2125.2006.02652.x
Abstract
Aims: Since cefuroxime mainly is excreted by renal filtration, dosing is currently based on serum creatinine (Scr) or creatinine clearance (CLcr). However, it has been suggested that cystatin C (CysC) is superior to Scr as a marker of renal function. The aim of this prospective study was to develop a population model that describes the pharmacokinetics of cefuroxime and to investigate the usefulness of CysC as a covariate of the model parameters.Methods: Ninety‐seven patients were studied (CLcr range 6.5–115 ml min−1). Blood samples (n = 407) for the determination of cefuroxime were withdrawn according to a sparse data sampling schedule and analysed by liquid chromatography mass spectrometry. The population analysis was performed in NONMEM.Results: A two‐compartment model described the data well. The biomarkers Scr, CLcr and CysC were evaluated as covariates on clearance (CL). The model that included CysC generated the best fit. In the final population model CL was a function of CysC and body weight, whereas V1 was only a function of body weight. Final parameter estimates (relative standard errors) were 6.00 (3.2%) l h−1, 11.4 (5.3%) l and 5.11 (11%) l for CL, V1 and V2, respectively.Conclusions: Based on the results of the present study, and because CysC is practical to use in the clinic, it is suggested that individual dosing of cefuroxime may be based on CysC rather than on Scr or CLcr. Furthermore, our final population model may be useful as a tool when designing new dosing schedules for cefuroxime.Keywords
This publication has 25 references indexed in Scilit:
- Serum Cystatin C is a Better Marker of Topotecan Clearance than Serum CreatinineClinical Cancer Research, 2005
- Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologiesEuropean Journal Of Cancer, 2002
- Continuous Infusion of ??-Lactam AntibioticsClinical Pharmacokinetics, 1998
- Efficacy of beta-lactam antibiotics: Integration of pharmacokinetics and pharmacodynamicsDiagnostic Microbiology and Infectious Disease, 1997
- The importance of modeling interoccasion variability in population pharmacokinetic analysesJournal of Pharmacokinetics and Biopharmaceutics, 1993
- High pressure liquid chromatographic analysis of the serum concentration of cefuroxime after an intravenous bolus injection of cefuroxime in patients with a coronary artery bypass graftingInternational Journal of Clinical Pharmacy, 1992
- A new approach to pharmacokinetic parameters: Estimation of cefuroxime during haemodialysisBiopharmaceutics & Drug Disposition, 1990
- Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiencyEuropean Journal of Clinical Pharmacology, 1983
- Determination of plasma and renal clearance of cefuroxime and its pharmokinetics in renal insufficiencyJournal of Antimicrobial Chemotherapy, 1979
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976